Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message| ()  

Looking for highly profitable companies but don’t know where to start? Here are some ideas to get you started.

We ran a screen on the biotech industry for stocks seeing consistent increases in diluted normalized EPS over the last four years. (We also made sure that all companies had positive earnings for all four years.)

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.‬

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these companies will continue seeing higher earnings? Use this list as a starting point for your own analysis.

List sorted by market cap.

1. Amgen Inc. (AMGN): Develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Market cap of $53.61B. Diluted normalized EPS increased from 3.72 to 4.16 during the first time interval (12 months ending 2008-12-31 vs. 12 months ending 2007-12-31). For the second time interval, diluted normalized EPS increased from 4.16 to 4.6 (12 months ending 2009-12-31 vs. 12 months ending 2008-12-31). And for the last time interval, the EPS increased from 4.6 to 4.97 (12 months ending 2010-12-31 vs. 12 months ending 2009-12-31). The stock has had a couple of great days, gaining 6.49% over the last week.

2. Gilead Sciences Inc. (GILD): Engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Market cap of $28.66B. Diluted normalized EPS increased from 1.64 to 2.08 during the first time interval (12 months ending 2008-12-31 vs. 12 months ending 2007-12-31). For the second time interval, diluted normalized EPS increased from 2.08 to 2.87 (12 months ending 2009-12-31 vs. 12 months ending 2008-12-31). And for the last time interval, the EPS increased from 2.87 to 3.51 (12 months ending 2010-12-31 vs. 12 months ending 2009-12-31). The stock has gained 4.38% over the last year.

3. Biogen Idec Inc. (BIIB): Develops, manufactures, and markets therapeutics in the areas of neurology, immunology, hemophilia, and oncology in the United States and internationally. Market cap of $26.90B. Diluted normalized EPS increased from 2.29 to 2.85 during the first time interval (12 months ending 2008-12-31 vs. 12 months ending 2007-12-31). For the second time interval, diluted normalized EPS increased from 2.85 to 3.38 (12 months ending 2009-12-31 vs. 12 months ending 2008-12-31). And for the last time interval, the EPS increased from 3.38 to 5.19 (12 months ending 2010-12-31 vs. 12 months ending 2009-12-31). The stock has gained 62.31% over the last year.

4. Illumina Inc. (ILMN): Develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Market cap of $3.24B. Diluted normalized EPS increased from 0.48 to 0.5 during the first time interval (52 weeks ending 2008-12-28 vs. 52 weeks ending 2007-12-30). For the second time interval, diluted normalized EPS increased from 0.5 to 0.61 (53 weeks ending 2010-01-03 vs. 52 weeks ending 2008-12-28). And for the last time interval, the EPS increased from 0.61 to 0.81 (52 weeks ending 2011-01-02 vs. 53 weeks ending 2010-01-03). The stock is a short squeeze candidate, with a short float at 17.86% (equivalent to 6.62 days of average volume). The stock has lost 58.46% over the last year.

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 4 Biotech Stocks With Consistently Rising EPS